Brief: Biophytis Obtains FDA Authorization To Initiate SARA-31 Phase 3 Study In Sarcopenia
11/09/2023 17:03
Sept 11 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS OBTAINS FDA AUTHORIZATION TO INITIATE SARA-31
PHASE 3
STUDY IN SARCOPENIA
Further company coverage: ALBPS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon